The short version
Just 2 companies supply this market — thin enough that a single exit would be felt immediately. It is in shortage right now — FDA lists the reason as “demand increase for the drug”.
Market view
dexmedetomidine hcl · Injection
2 marketed package NDCs · 2 active manufacturers
Same drug class
Other molecules FDA puts in Central alpha-2 Adrenergic Agonist, with whether each is in shortage right now. Same class is not the same drug — substitution is a clinical decision, and this is a supply picture, not a recommendation.
- dexmedetomidine hydrochloride in 0.9% sodium chloride· in shortage
- dexmedetomidine· in shortage
- dexmedetomidine hydrochloride· in shortage
- clonidine hci· 1 maker
- clonidine hydrochloride oral· 1 maker
- dexmedetomidine hydrochloride in sodium chloride· 1 maker
- tizandine· 1 maker
- clonidine transdermal system· 2 makers
- guanfacine er· 2 makers
- tizanidine hcl· 2 makers
- gaunfacine· 3 makers
- methyldopa· 4 makers
Common questions
- Is Dexmedetomidine hcl in shortage right now?
- Yes. FDA currently lists Dexmedetomidine hcl in shortage, with the reason given as "demand increase for the drug". This page is rebuilt every morning from FDA's shortage database.
- Who makes Dexmedetomidine hcl?
- 4 companies have marketed Dexmedetomidine hcl in the last 30 days, according to the FDA NDC Directory. Every manufacturer and package is listed on this page.
Shortage reports for this molecule
- In shortage now — Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 0143-9532-25)Apr 10, 2020
All marketed products
Expand a strength to see its dosage forms, then package sizes, then each manufacturer and NDC. Click an NDC for its full detail page.